Objective
Recent technological advances have brought the implementation of personal and precision medicine in the clinic within reach. In this project, we are proposing to use zebrafish as a novel, efficient tool to improve the clinical diagnosis and treatment of Marfan Syndrome (MFS), a rare genetic disorder with a wide spectrum of clinical features. Since there is no definitive cure for MFS, patients need lifelong supportive treatment to prevent morbidity and mortality related to cardiovascular complications. Together with the detection of a number of syndromic symptoms, positive diagnosis of MFS relies on the identification of a deleterious mutation in the fibrillin-1 (FBN1) gene. Nevertheless, genetic testing often leads to the discovery of FBN1 variants which are not unequivocally linked to disease development. Current practice relies on the evaluation of historical and predictive parameters to classify variants of unknown significance as potentially causal mutations, but no biological model exists to efficiently validate the genetic classifications.
This project aims to make optimal use of the combination of the know-how of the researcher, Dr. Sips, in the field of cardiovascular physiology and animal models of disease, with the clinical expertise of the supervisor, Prof. De Backer, in the diagnosis and treatment of MFS patients. The goal is to develop a zebrafish-based model that will allow for the quick classification of unknown variants in the FBN1 gene to aid in the diagnosis of MFS. In addition, the model will allow an efficient screening of drug libraries to look for potential new therapies, which might make it possible to find patient-specific treatments.
Taken together, this project aims to take advantage of the synergy between the researcher and the supervisor in order to develop a novel strategy for a personalized approach to medicine. MFS is studied as a proof-of-concept clinical challenge with unmet needs in diagnosis and treatment.
Fields of science (EuroSciVoc)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-RI - RI – Reintegration panel
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
9000 GENT
Belgium
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.